Avita Taps Sinopharm To Ramp-Up China Sales Of ReCell "Spray-On-Skin"
Executive Summary
Avita Medical has awarded Sinopharm with exclusive rights to distribute across China ReCell, an autologous cell harvesting device that creates a cellular suspension made from the patient’s own skin for use in advanced wound care and the treatment of skin defects. This "spray-on-skin" can be used in conjunction with all other key wound care approaches and is currently in a multi-center pivotal trial to obtain US FDA premarket approval, which is expected in Q3 2017.